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Abstract
Background: Long-lasting impairment of the immune system is believed to be the underlying reason for delayed
deaths after surviving sepsis. We tested the hypothesis of persisting changes to the immune system in survivors of
sepsis for the first time.
Methods: In our prospective, cross-sectional pilot study, eight former patients who survived catecholamine-
dependent sepsis and eight control individuals matched for age, sex, diabetes and renal insufficiency were enrolled.
Each participant completed a questionnaire concerning morbidities, medications and infection history. Peripheral
blood was collected for determination of i) immune cell subsets (CD4+, CD8+ T cells; CD25+ CD127- regulatory T
cells; CD14+ monocytes), ii) cell surface receptor expression (PD-1, BTLA, TLR2, TLR4, TLR5, Dectin-1, PD-1 L), iii) HLA-
DR expression, and iv) cytokine secretion (IL-6, IL10, TNF-α, IFN-γ) of whole blood stimulated with either
α-CD3/28, LPS or zymosan.
Results: After surviving sepsis, former patients presented with increased numbers of clinical apparent infections,
including those typically associated with an impaired immune system. Standard inflammatory markers indicated a
low-level inflammatory situation in former sepsis patients. CD8+ cell surface receptor as well as monocytic HLA-DR
density measurements showed no major differences between the groups, while CD4+ T cells tended towards two
opposed mechanisms of negative immune cell regulation via PD-1 and BTLA. Moreover, the post-sepsis group
showed alterations in monocyte surface expression of distinct pattern recognition receptors; most pronouncedly
seen in a decrease of TLR5 expression. Cytokine secretion in response to important activators of both the innate
(LPS, zymosan) and the adaptive immune system (α-CD3/28) seemed to be weakened in former septic patients.
Conclusions: Cytokine secretion as a reaction to different activators of the immune system seemed to be
comprehensively impaired in survivors of sepsis. Among others, this could be based on trends in the
downregulation of distinct cell surface receptors. Based on our results, the conduct of larger validation studies
seems feasible, aiming to characterize alterations and to find potential therapeutic targets to engage.
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Background
Sepsis remains a big challenge in modern intensive care
medicine and is still a leading cause of death [1–3]. It is an
interwoven immune reaction to distinct microorganisms,
which comprises systemic inflammatory response syn-
drome (SIRS) with a “cytokine storm” accompanied by the
counteracting, so-called compensatory anti-inflammatory
response syndrome (CARS) [4, 5].
In the case of overwhelming CARS, the phenomenon of
immune paralysis occurs due to immune cell apoptosis
and functional impairment of lymphocytes and phago-
cytes, also associated with increased anti-inflammatory
and decreased pro-inflammatory cytokine production
[6–9]. Overshooting of the anti-inflammatory response
predisposes the host to secondary bacterial infection,
infection with opportunistic microorganisms and re-
activation of latent viruses [7, 10–13]. In contrast to
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the initial causative insult of sepsis, which can be
treated by source control and anti-infective therapy,
no therapeutic or preventive strategies are established
to combat the deleterious effects of immune paralysis
during the period of CARS [14]. Furthermore, the im-
mune cell phenotype of patients who die from sepsis
has features consistent with immunosuppression [15].
Patients with impaired immune function are prone to
incomplete recovery from sepsis. They often present
with typical syndromes that follow the SIRS-CARS reac-
tion: persistent inflammation-immunosuppression catab-
olism syndrome (PICS) and multiple organ dysfunction
syndrome (MODS) [16]. Besides sophisticated intensive
care treatment, a relevant number of survivors of the
initial septic event ultimately fall victim to PICS or
MODS in the long-term.
Even after complete recovery many patients who re-
cover from sepsis have an impaired quality of life for
years and are found to have increased mortality [17–19].
Studies have illustrated ongoing mortality of up to 43 %
after one year [17], 44.9 % after two years [20] and
74.2 % after five years beyond hospital discharge [21].
Sepsis-related long-lasting impairment of the immune
system is believed to be the underlying reason for these
delayed deaths in those who initial survive sepsis. How-
ever, studies investigating the immune status of survivors
of sepsis in humans are missing. In this prospective,
cross-sectional pilot study we aimed to explore for the
first time the phenomenon of sepsis-induced long-term
immune paralysis (SLIP) in a limited number of patients
who survived catecholamine-dependent sepsis.
Methods
Enrollment of patients who had previously survived sepsis
The local ethics committee at the Medical Faculty of the
Justus-Liebig-University Gießen, Germany approved the
study protocol (trial code: 291/13). We identified all pa-
tients who had been diagnosed with sepsis (ICD10: A41.X)
and who had required vasopressors or inotropes (catechol-
amine-dependent sepsis), and had been treated on the
interdisciplinary surgical intensive care unit at Gießen Uni-
versity Hospital between January 2011 and December 2013.
Data were extracted from our patient data management
system ICUData (IMESO® GmbH, Giessen, Germany). All
patients identified were contacted by mail. After evaluation
of possible exclusion criteria, written informed consent was
collected and individuals were enrolled in the study. Exclu-
sion criteria were: onset of sepsis less than nine months or
more than 60 months prior to the date of investigation,
pregnancy, participating in another interventional study,
chronic viral infections (HIV, hepatitis), end-stage renal fail-
ure, autoimmune diseases and patients taking high-dose
corticosteroids (hydrocortisone >200 mg/day or equivalent)
or other immunosuppressive medications.
Eight individuals who had never suffered from sepsis
were matched for age, sex, diabetes and renal insufficiency
and checked for the presence of exclusion criteria, and
were subsequently enrolled as controls after giving written
informed consent. Blood (50 mL) was collected in hepa-
rinized, ethylenediaminetetraacetic acid (EDTA) or serum
tubes by peripheral venipuncture from each study partici-
pant and immediately processed.
Questionnaire
All study participants were asked to complete a 63-item
questionnaire on current and past morbidities, current
medications and clinically apparent infections during the
last twelve months. In addition, former data on the
sepsis-associated hospital stay were extracted from our
patient data management system (focus of infection and
time since sepsis).
Standard laboratory parameters
For standard laboratory tests, blood samples were proc-
essed in the routine hospital laboratory. Blood count (white
blood cells, red blood cells, hemoglobin, hematocrit, mean
corpuscular volume, mean corpuscular hemoglobin, mean
corpuscular hemoglobin concentration and platelets)
and additional parameters of relevance in the context
of infections (fibrinogen, aspartate transaminase, alanine
transaminase, γ-glutamyl transferase, C-reactive protein
(CRP) and procalcitonin) were measured according to in-
house standards.
Characterization of immune cell subsets
To assess the number of T cell subsets and monocytes,
whole blood was stained and measured by flow cytome-
try as described in detail below. The percentage of CD4+
and CD8+ T cells was calculated as the fraction of all
CD3+ events, while the amount of regulatory T cells
(CD4+ CD25+ CD127-) was calculated as the fraction of
all CD4+ events. Last, the percentage of monocytes was
calculated as the amount of CD14+ cells from all mea-
sured cellular events.
Quantitative HLA-DR analysis on monocytes
Expression of human leucocyte antigen-antigen D-related
(HLA-DR) on CD14+ monocytes was measured by flow
cytometry according to the manufacturer’s recommenda-
tions (Quantibrite HLA-DR/Monocyte antibody cocktail,
BD Bioscience, Heidelberg, Germany). Briefly, 50 μL of
EDTA-anticoagulated whole blood was incubated with
20 μl of the antibody cocktail and incubated for 30 min.
Afterwards, erythrocyte lysis was performed by adding
450 μl FACS Lysing solution (BD Bioscience, Heidelberg,
Germany) and further incubation for 15 minutes. Meas-
urement was immediately done on a FACSCalibur flow
cytometer (BD Bioscience). In addition, a 4-point
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calibration curve (Quantibrite PE Beads, BD Bioscience)
was also measured daily to enable the transformation of
the measured sample values to molecules of HLA-DR.
Expression of cell surface proteins
Cell surface expression analysis was performed by flow cy-
tometry. For each target of interest, 100 μL whole blood
was incubated with the corresponding antibodies and in-
cubated for 30 minutes at 4 °C, followed by a lysing step
of 15 minutes at room temperature after addition of 2 mL
fluorescence-activated cell sorting (FACS) lysing solution.
Finally, the cells were washed twice (1.000 rpm, 5 minutes,
4 °C) with cold phosphate-buffered saline (PBS; Thermo
Fisher Scientific, Waltham, MA, USA) containing 1 %
bovine serum albumin (fraction V, protease-free; Carl
Roth, Karlsruhe, Germany).
The following antibodies were used for the identification
of immune cell subsets: fluorescein isothiocyanate (FITC)-
CD3 (BD Bioscience, #555916), FITC-/phycoerythrin (PE)-
CD4 (BD Bioscience, #555346/555347), PE-CD8 (BD Bio-
science, #555367), FITC-CD14 (BD Bioscience #555397),
PE-CD25 (BD Bioscience, #555432), Alexa Fluor 647-
CD127 (BD Bioscience, #558598). For the quantitative
measurement of expression levels on T cells, the following
antibodies were used: programmed cell death 1 (PD-1)
(Biolegend, San Diego, USA, #329908), B- and T-
lymphocyte attenuator (BTLA) (Biolegend, #344510), or
cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)
(Biolegend, #349908) (all conjugated to allophycocyanin
(APC)). For the quantitative measurement of expression
levels on monocytes, the following antibodies were used in
addition: toll-like receptor (TLR)2 (Biolegend, #309708),
TLR4 (Biolegend, #312806), TLR5 (Abcam, Cambridge,
UK, #4.5119), Dectin-1 (Biolegend, #355404) or pro-
grammed cell death ligand 1 (PD-1 L) (Biolegend,
#329706) (all conjugated to PE). Furthermore, for every
antibody used, an according sample was stained with the
same amount of isotype-matched non-binding antibody
(isotype control). Percentages of positive cells represent the
fraction of cells with fluorescence above isotype control.
To obtain robust and reliable quantitative results with-
out bias due to the day-to-day variance of the instru-
ment, we measured a 4-point calibration curve for both
PE and APC (QUANTUM™ MESF beads, Bangs Labora-
tories, Fishers, IN, USA). Fluorescence intensity of each
sample was normalized by subtracting the staining in-
tensity of the according isotype control. Subsequently,
conversion to molecules of equivalent soluble fluoro-
phore (MESF) was done be recalculating the normalized
intensity to the results of the calibration curve.
Cytokine secretion of ex vivo-stimulated whole blood
For the functional assessment of the immune cells,
whole blood was diluted 1:1 with RPMI1640 containing
proprietary GlutMAX™ (Thermo Fisher Scientific,
Waltham, MA, USA) and 5 % fetal bovine serum (Ultra-
low endotoxin; Cell Concepts GmbH, Umkirch, Germany)
and incubated with α-CD3/28 (eBioscience, Frankfurt,
Germany; T cell stimulation), ultrapure lipopolysaccharide
(LPS) (0111:B4; TLR4 agonist, activates monocytes and
dendritic cells) or depleted zymosan (β-1,3-D-glucan;
TLR2/Dectin-1 agonist, activates monocytes and dendritic
cells) (both Invivogen, San Diego, CA, USA).
For T cell activation, microplates were coated in ad-
vance by incubation of 50 μL α-CD3 antibody solution
(10 μg/mL) for 24 h. After incubation, the wells were
washed twice with sterile PBS and 300 μL of diluted
blood and α-CD28 antibody (2 μg/Ml) were added. LPS
and zymosan stimulation was performed directly in the
blood by adding the agonists in a final concentration of
100 ng/mL and 25 μg/mL, respectively.
All stimulation was done in triplicate for 24 h. After
incubation, the samples were centrifuged (3.000 rpm,
5 minutes) and supernatant recovered. As the readout,
the secretion of cytokines (IL-2, IL-4, IL-6, IL-10, IL-
17A, TNF and IFN-γ) were measured using a multiplex
Th1/Th2/Th17 cytometric bead array (BD Bioscience).
Statistical analysis
The present pilot study was set up with an estimating
intention to assess the variances of the endpoints to en-
able sample size estimation for further studies. Because
of lacking data, no a priori sample size calculation was
performed for this study. Based on the study intention
and the small sample size, no group comparisons were
performed. Visualization in scatter plots was done using
GraphPad Prism (Version 5.0f, GraphPad Software, La
Jolla, CA, USA).
Results
Enrollment and specimen collection
Long-term survivors of catecholamine-dependent sep-
sis were identified (n = 172) and contacted by mail
9–52 months after the septic event. Of all interested
responders (n = 14), 8 former patients were eligible to
be enrolled in the study. Afterwards, 8 individuals
matched for age, sex, diabetes, and renal insuffi-
ciency, who had never suffered from sepsis, were en-
rolled as controls.
The clinical characteristics of the patients who had
survived sepsis and the control group are shown in
Table 1. In the post-sepsis group, the median period be-
tween sepsis and the study time point was 26 (9–52)
months. The most frequent focus of infection was uro-
genital (50 %), followed by necrotizing fasciitis (25 %)
and pulmonary or endoprosthesis infection (12.5 %
each). Further clinical characteristics (especially age, sex,
diabetes and renal insufficiency) were similar in the two
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groups. However, distinct differences were found in pre-
scribed medications e.g., anticoagulant, blood pressure
and diuretic medication.
Characteristics of clinically apparent infections during the
previous year
Of the sepsis survivors 62.5 % had experienced at least
one infection during the previous 12 months (Table 2).
One of those patients suffered five episodes of upper
airway infection. At least one episode of antibiotic
treatment was prescribed to four individuals in the
sepsis survivors. Three different types of infection oc-
curred (oral candidiasis, herpes zoster and lower air-
way infection), which are typically associated with an
impaired immune system. None of the patients in the
control group was diagnosed with an infection or was
treated with anti-infective medication.
Exclusion of current acute infections
Standard inflammatory markers were determined to
screen for current infectious diseases. White blood cell
count was within the physiological range in all but one
individual (13.2 cells/μL × 103) in the control group
(Table 3). CRP was slightly elevated in eight sepsis survi-
vors and seven control individuals. Despite all values be-
ing <50 mg/L (threshold for severe infection), there was
a minor trend towards increased CRP levels in patients
with a history of sepsis. Procalcitonin (PCT) was mar-
ginally increased (0.1; 0.1; 0.2 ng/ml) in three sepsis sur-
vivors. Thus, the presence of relevant but not clinically
apparent infective disorders at the time of enrollment,
which could affect our analysis, was unlikely. However,
Table 1 Clinical characteristics of controls and patients who
survived sepsis
Control (n = 8) Sepsis (n = 8)
Age, median (range) 59 (34–85) 60 (36–82
Male sex 5 (62.5) 5 (62.5)
Body mass index, kg/m2, median
(range)
26.4 (18.1–34.3) 24.4 (22.2–40.4)
Time since sepsis, months, median
(range)
26 (9–52)
Infection focus responsible for sepsis
Urogenital 4 (50)
necrotizing fasciitis 2 (25)
Pulmonary 1 (12.5)
Endoprothesis infection 1 (12.5)
Morbidities (current and past)
Heart and circulation
Myocardial infarction 2 (25) 2 (25)
Myocarditis 0 (0) 0 (0)
Stroke 1 (12.5) 0 (0)
Pulmonary artery embolism 0 (0) 0 (0)
Thrombosis 0 (0) 0 (0)
Airway and lung
Asthma 0 (0) 0 (0)
chronic bronchitis 0 (0) 2 (25)
Pneumonia 0 (0) 2 (25)
Exacerbation of chronic obstructive
pulmonary disease
0 (0) 1 (12.5)
Kidney
Insufficiency 1 (12.5) 1 (12.5)
Pyelonephritis 0 (0) 1 (12.5)
Glomerulonephritis 0 (0) 0 (0)
Gastrointestinal tract and metabolism
Chronic inflammatory bowel disease 0 (0) 0 (0)
Ulcus 0 (0) 1 (12.5)
Gastritis 1 (12.5) 1 (12.5)
Diabetes 3 (37.5) 3 (37.5)
Current medications 6 (75) 7 (87.5)
Anticoagulants 0 (0) 3 (37.5)
Anti-platelet agents 5 (62.5) 3 (37.5)
Antihypertensive medication 2 (25) 5 (62.5)
Diuretics 1 (12.5) 4 (50)
Diabetes medication 3 (37.5) 3 (37.5)
Insulin 2 (25) 3 (37.5)
Absolute number (percentage), if not otherwise specified
Table 2 Characteristics of clinically apparent infections during
the previous year
Control (n = 8) Sepsis (n = 8)
Individuals with ≥1 infection 0 (0) 5 (62.5)
Incidence per annum, number (range) 1 (0–5)
Outpatient 2 (25)
Stationary 2 (25)
Antibiotic therapy 4 (50)
Application of blood components 2 (25)
Site of infection
Upper airway 3 (37.5)
Lower airway 2 (25)
Urogenital 0 (0)
Gastrointestinal 1 (12.5)
Central nervous 0 (0)
Special infectious entities
Herpes zoster 1 (12.5)
Herpes simplex 0 (0)
Oral candidiasis 1 (12.5)
Cytomegalovirus (re)infection 0 (0)
Absolute number (percentage), unless specified otherwise
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the slightly elevated CRP and PCT values in sepsis survi-
vors indicate a chronic low-level inflammatory status.
Characterization of circulating immune cells
CD4+ and CD8+ subsets of CD3+ T cells were determined
by flow cytometry analysis (Fig. 1). Additionally, the
percentage of regulatory T cells (CD25+ CD127- Tregs)
and CD14+ (antigen-presenting) monocytes as part of all
leukocytes were determined. No substantial differences
between the two groups were observed.
Furthermore, we determined expression levels for
important negative regulators of lymphocyte function.
Therefore we measured PD-1, CTLA-4 and BTLA re-
ceptor expression within the CD4+ and CD8+ T cell
subsets by 1) quantifying the percentage of receptor-
positive cells and 2) assessing a surrogate parameter
of the cell surface receptor density (MESF) (Fig. 2).
No expression of CTLA-4 was measurable (data not
shown). In CD4+ cells of sepsis survivors, the recep-
tor density of PD-1 appeared to be downregulated,
but was upregulated for BTLA. In CD8+ cells no substan-
tial changes were seen. In summary, this is indicative
of two opposing mechanisms of negative immune cell
activation feedback in CD4+ cells in patients who
have survived sepsis.
Next we sought to clarify whether the initiation of innate
immune responses of monocytes via pattern recognition
receptors and the negative regulatory molecule PD-1 lig-
and (PD-1 L) might be disturbed in sepsis survivors due to
modified expression levels. Therefore, we determined the
surface protein expression of different toll-like-receptors
(TLR2, TLR4, TLR5), Dectin-1, and PD-1 L (Fig. 3). For
TLR4 and PD-1 L there were no substantial differences be-
tween the two groups. Dectin-1-positive cells were more
frequent but Dectin-1 density was not affected in the sep-
sis survivors. There was a slight increase in TLR2+ cell
count and receptor density. The most notable and coher-
ent effect was seen for TLR5, which is a fundamental
player in pathogen-associated molecular pattern rec-
ognition (bacterial flagellin) and therefore an activator
of innate immunity. Its receptor-positive cell count
and especially the receptor density were substantially
decreased, which points towards a selectively impaired
innate immune system in this special aspect.
No evident differences were seen in the monocytic
HLA-DR receptor density as a surrogate marker of glo-
bal immune function (Fig. 4).
Cytokine secretion of ex-vivo-stimulated whole blood
Last, we determined the immune competence of individ-
ual patients to react to distinct inflammatory stimuli.
Whole blood from sepsis survivors and controls was
either incubated with the T cell activator α-CD3/28,
or the monocyte/macrophage-activators LPS (via TLR4)
or zymosan (via TLR2/Dectin-1). Subsequently, effects on
the expression of the cytokines IL-2, IL-4, IL-6, IL-10, IL-
17A, TNF-α and IFN-γ were measured (Fig. 5). No IL-2,
IL-4, and IL-17A secretion was detectable (data not
shown). For the other parameters determined, the post-
sepsis group had decreased cytokine responses. There
were pronounced trends towards lower IFN-γ production
after stimulation with α-CD3/28 and IL-10 production
after LPS activation. Most impressively, stimulation
with zymosan, a yeast surface protein, was followed
Table 3 Blood count and additional laboratory parameters
Control (n = 8) Sepsis (n = 8)
Median Perc 05 Perc 95 Median Perc 05 Perc 95
WBC, cells/μL × 103 5,6 3,8 13,2 7,7 5,3 9,9
Erythrocytes, cells/μL × 106 4,8 3 5,3 4,55 4,1 6,1
Hemoglobin, g/L 140 88 158 137 106 170
Hematocrit, % 0,41 0,26 0,48 0,42 0,35 0,51
MCV, fL 86,5 85 93 89,5 83 96
MCH, pg 29,65 28,7 31,9 28,9 25,8 31,7
MCHC, g/L 340,5 331 353 327,5 306 342
Platelets, cells/μL × 103 268 179 346 261 231 320
Fibrinogen, g/L 3,38 2,54 5,43 3,55 2,29 5,21
AST, U/L 28 16 33 20 11 55
ALT, U/L 25 12 52 22 16 73
GGT, U/L 13 7 81 34 9 155
CRP, mg/L 1,76 0 32,53 10,01 0,88 23,65
PCT, ng/mL 0 0 0 0 0 0,2
perc percentile, WBC white blood cell count, MCV mean corpuscular volume, MCH mean corpuscular hemoglobin, MCHC mean corpuscular hemoglobin
concentration, AST aspartate transaminase, ALT alanine transaminase, GGT γ-glutamyl transferase, CRP C-reactive protein, PCT procalcitonin
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by substantially reduced production of IL-6, IL-10 and
TNF-α. The observed responses did not depend on the
sole number of leucocytes present in the sample. In fact,
only the LPS-induced TNF secretion correlated signifi-
cantly with the number of leucocytes, but paradoxically
the relationship was negative (Spearman r –0.5303,
p = 0.0346; data not shown). All of the abovementioned
cytokines were also assessed in native plasma from the
participants, to rule out the possibility of their presence as
chronic immunogenic stressors, inducing maladaptation
of the immune cells. We found no detectable concentra-
tion for any cytokine (data not shown).
Fig. 2 Determination of the pattern of expression of specific receptors on CD4+ and CD8+ T cells. Peripheral blood was collected from eight
survivors of sepsis and matched controls and stained for the indicated markers, followed by determination of percent positive relative to isotype
control staining (bottom line) and quantification of fluorescence intensity by molecules of equivalent soluble fluorochrome (MESF) calculation
(upper line) as described in “Methods”. Each data point represents an individual patient. Horizontal lines indicate median values. PD programmed cell
death, BTLA B- and T-lymphocyte attenuator
Fig. 1 Characterization of immune cells subsets. Peripheral blood was collected from eight survivors of sepsis and matched controls and analyzed
by flow cytometry to determine the percentage of circulating CD4+ and CD8+ subsets of CD3+ T cells, the amount of regulatory T cells (CD25+
CD127- Treg) as a fraction of all CD4+ cells, and CD14+ monocytes of all leucocytes. The markers used are described in “Methods”. Each data
point represents an individual patient. Horizontal lines indicate median values
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Taken together, the net effect of detection and reaction
to important activators of both the innate and the adap-
tive immune system seems to be impaired in survivors
of sepsis.
Discussion
In our prospective, cross-sectional study we aimed to ex-
plore the phenomenon of sepsis-induced long-term im-
mune paralysis. We identified patients who survived an
episode of catecholamine-dependent sepsis 9–60 months
prior to enrollment. General health status, immune cell
subsets, cell surface receptor expression, HLA-DR ex-
pression, and cytokine secretion of stimulated whole
blood were determined. We conducted our study to
shed light on the phenomenon of persisting high
morbidity in survivors of sepsis. In their review Winters
et al. reported 1-year mortality after hospital discharge,
which differed between 3 % and 43 % in 17 distinct stud-
ies [17]. In one other study, the 2-year mortality rate
after hospital discharge was 44.9 % among individuals
surviving severe sepsis. This was 1.5 times higher than
the in-hospital mortality rate in the same study [20]. A
very late increment for sepsis-related mortality was ob-
served in a study that reported 1-year mortality of
51.4 %, increasing to 74.2 % 5 years after hospital dis-
charge [21]. An impaired immune response as one se-
quelae of previous sepsis is believed to be a major
contributing factor in these delayed deaths [16, 22]. To
our knowledge studies investigating this phenomenon
are rare, especially in humans. In distinct murine
models, Marwart et al. demonstrated sepsis-induced loss
of naive T cells but no prolonged defects in T cell func-
tion [23]. On analysis of myeloid cells after polymicro-
bial sepsis in mice, precursors of dendritic cells in the
bone marrow were found to develop into regulatory
dendritic cells that mediated immunosuppression [24].
Our own investigations showed that human sepsis in-
duces distinct epigenetic changes in immunologically
relevant genes that could ultimately contribute to func-
tional changes in monocytes [25]. As these modifications
are persistent and can be propagated, changes in basal
regulatory mechanisms might also affect the immune
function after surviving sepsis [22]. Additionally, effects
on behavioral, affective and molecular responses in the
brain of mice are shown after surviving LPS-induced
systemic inflammation [26, 27].
There was almost complete matching of clinical char-
acteristics that likely modify immune function (age, sex,
presence of diabetes and renal function). As a result, the
Fig. 3 Determination of expression pattern of specific receptors on monocytes. Peripheral blood was collected from eight survivors of sepsis
and matched controls and stained for the indicated markers, followed by determination of percent positive relative to isotype control staining
(bottom line) and quantification of fluorescence intensity by molecules of equivalent soluble fluorochrome (MESF) calculation (upper line)
as described in “Methods”. Each data point represents an individual patient. Horizontal lines indicate median values. TLR toll-like receptor, PD-1 L
programmed cell death ligand
Fig. 4 Determination of human leukocyte antigen (HLA)-DR
expression on monocytes. Peripheral blood was collected from eight
survivors of sepsis and matched controls and HLA-DR expression
was measured. Each data point represents an individual patient.
Horizontal lines indicate median values
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two groups were comparable in the context of the
present study. The hypothesis of impaired immunity in
survivors of sepsis is supported by the results of the clin-
ical status questionnaire (Table 2). First, the observations
revealed continuing infections even months and years
after surviving sepsis. Second, the need for antibiotic
drug prescriptions in four patients and two hospital ad-
missions emphasize the severity and relevance of the in-
fections. Third, we observed infections that are typically
associated with impaired immune function: oral candid-
iasis, herpes zoster and lower airway infection. This is in
line with mouse models, which indicate that survivors of
septic shock are susceptible to infection with pathogens
that are usually innocuous [24, 28–30]. Notably, these
types of infection are likely to reduce the patient’s qual-
ity of life, an assumption that is consistent with previous
reports describing impaired quality of life secondary to
serious illness [17, 20].
The standard inflammatory markers were in the nor-
mal range or slightly increased, sufficient to exclude
clinically relevant infectious episodes at the time of en-
rollment (Table 3). However, comparing the two study
groups, the sepsis survivors had low CRP values, but
higher CRP values than controls, and more frequently
had slightly elevated PCT. This observation also sup-
ports the perception that sepsis is followed by a long-
lasting, low-grade chronic inflammatory state.
Sepsis induces a comprehensive loss of myeloid cells
and lymphocytes including CD4+ and CD8+ T cells [8].
Boomer et. al. observed a reduction in CD4+ and CD8+ T
cells in the acute phase and an increase of regulatory T
cells in the process of sepsis [31]. As shown by our own
results the distribution of subsets seems to normalize in
the long term after surviving sepsis (Fig. 1). Nevertheless,
the presence of certain cells does not imply the exertion of
function and several studies, mainly conducted in animals,
show the presence of sustained functional alterations after
severe infection [22, 28].
For the next investigation we therefore determined the
expression levels of cell surface receptors on different T
cell subsets (Fig. 2) and on monocytes (Fig. 3). In a lon-
gitudinal study, Boomer et. al. observed a trend in the
MESF increase in PD-1 at the onset of sepsis [31]. In an-
other study there was upregulation of PD-1 on T cells
and PD-L1 on monocytes in patients with septic shock
[32]. Relevant to the potential for clinical implementa-
tion, the blockade of PD-1 and CTLA-4 improves sur-
vival in primary and secondary fungal sepsis in mice
[33]. In our study, we found contrary results for PD-1 in
sepsis survivors in the long term (Fig. 2). However,
BTLA receptor expression trended towards upregula-
tion. As both are members of the important negative
regulators of T cell function, clear-cut conclusions are
hard to draw. It appears that the resulting phenotype
might be highly dependent on the individual immune
system, raising a question about the influential variables.
In our study, patients who survived an episode of sep-
sis had alterations in monocyte surface expression of
Fig. 5 Cytokine secretion of ex-vivo-stimulated whole blood. Peripheral blood was collected from eight survivors of sepsis (S) and matched controls
(C). Whole blood was stimulated with either CD3/28 antibody (α-CD3/28), lipopolysaccharide (LPS) or Zymosan. Supernatants were harvested after
24 h and TNF-α, interferon-γ (IFN-γ), and IL-6 and IL-10 were measured by enzyme-linked immunosorbent assay. Each data point represents an
individual patient. Horizontal lines indicate median values. CD cluster of differentiation
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pattern recognition receptors (Fig. 3). The most notable
effect was in substantially decreased TLR5 expression.
As TLR5 recognizes flagellin, which is the main compo-
nent of bacterial flagella, the downregulation of TLR5
may in consequence contribute to impaired detection of
certain bacteria by phagocytes.
Decreased surface HLA-DR expression on monocytes
is a reliable surrogate marker of global immunosuppres-
sion and its value predicts mortality and development of
nosocomial infection in patients suffering from sepsis
[34–39]. As a reasonable consequence, survivors of sep-
sis in our study had no substantial differences in HLA-
DR expression compared to controls (Fig. 4).
Boomer et al. have already showed that peripheral
blood mononuclear cells isolated from whole blood
7 days after onset of sepsis have impaired secretion of
IFN-γ when stimulated with α-CD3/28 [31]. According
to our results, this trend appears to continue even months
and years post-sepsis (Fig. 5). In contrast to our findings,
the values for IL-6, IL-10 and TNF-α after α-CD3/28
stimulation were increased in that study [31]. As these pa-
tients were still hospitalized and in an acute immune con-
dition, this could be one explanation for the difference. In
another study from Boomer et. al., the cytokine secretions
of TNF-α, IFN-γ, IL-6 and IL-10 were globally decreased
after LPS and α-CD3/28 stimulation in patients who died
from sepsis [15]. The same trends were observable in our
group of sepsis survivors (Fig. 5).
Despite our valuable findings, there are several limita-
tions in our study. First, our investigation is a pilot study
and therefore we only examined a small number of pa-
tients. As a result we were only able to demonstrate pro-
nounced trends and this is why our investigations need
extensive revalidation with a larger sample size. Second,
our control population consisted of mostly healthy indi-
viduals besides the described matching parameters. As
so, we did not compare patients who had survived sepsis
with patients who had survived non-septic critical
illness. Therefore, our findings may be due to surviving
an acute critical illness or non-matched co-morbidities
and not necessarily from surviving sepsis. Third, we did
not know the patients’ immune status before sepsis. The
septic event could have evolved from previous differ-
ences in immune system function. These differences
could be still detectable after sepsis, but not necessarily
be a consequence of surviving sepsis. As most individuals
had previously had urosepsis, different types of sepsis (e.g.,
abdominal sepsis) might have another fundamental effect
on immune function and need to be evaluated. Further-
more, each individual was only investigated once and
therefore, we were not able to identify possible changes in
immune cell function over time.
We conducted this study as a basis for further investiga-
tion of a poorly studied group of patients: the survivors of
sepsis. Even though long-lasting impairment of the im-
mune system is believed to be the underlying reason for
delayed sepsis-related death and to impact quality of life,
studies investigating the immune status of survivors of
sepsis in humans are missing. In the future, comprehen-
sive studies need to test the correlation between the rea-
sons (alterations of the immune cells) and the effects
(quality of life and survival). Post-septic patients may re-
quire specific diagnostic tools and the results could enable
us to identify patients who might benefit from structured
post-sepsis care. Individualized medicine does not stop at
the hospital door and therefore, we need to reconsider
what comes after acute critical care.
Conclusions
The reactivity of immune cells to different activators ap-
pears to be comprehensively impaired in survivors of
sepsis. Among other reasons, this could be based on the
downregulation of distinct cell surface receptors. Never-
theless, we believe that our findings might merely repre-
sent the tip of the iceberg, and further validation studies
in larger cohorts are needed to clearly track the changes
and the underlying molecular mechanism and their bio-
logical relevance.
Key messages
 In the long term, survivors of sepsis had increased
numbers of clinically apparent infections and a
low-level inflammatory status based on the
standard inflammatory markers
 In the post-sepsis group, there were alterations in
monocyte surface expression of distinct pattern
recognition receptors, most pronouncedly observed
in decreased TLR5 expression
 Cytokine secretion in response to important
activators of both the innate (LPS and zymosan) and
the adaptive immune system (α-CD3/28) appeared
to be weakened in sepsis survivors
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